Skip to main content


RheumNow Podcast square

Great and Not So Great (9.30.2022)

Sep 30, 2022

This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.

Read Article

2022 Lasker Award Winners

Sep 29, 2022

The Lasker Foundation has announced the winners of its 2022 Lasker Awards, widely regarded as America’s top biomedical research prize since its creation more than 75 years ago. Here's a look at the award winners and their important contributions to biomedical research.

Read Article

Immune Benefits to Sound Sleep

Sep 26, 2022

The revitalizing powers of sleep are numerous but what are the consequences to inadequate sleep? A current report in the Journal of Experimental Medicine shows the connection between sleep and immune function as measured in mice and humans; specifically, a good night’s sleep promotes normal

Read Article
RheumNow Podcast square

Heavy Metal Rheumatology (9.23.2022)

Sep 23, 2022

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Sep 20, 2022

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
COVID infection mask

COVID Outcomes in Dermatomyositis

Sep 09, 2022

A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).

Read Article
RheumNow Podcast square

Does Fibromyalgia Need B12? (9.9.2022)

Sep 09, 2022

Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from

Read Article

Global Trends Informing the Future of Rheumatoid Arthritis

Sep 06, 2022

Finkh et al report on the prevalence and interesting trends in rheumatoid arthritis (RA), including its higher prevalence in industrialized countries and declining disease severity over time. 

The article appears in Nature Reviews Rheumatology and discusses worldwide variance

Read Article
RheumNow Podcast square

Goofy But True

Sep 02, 2022

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on

  1. After historic drop in 2020 (COVID), life expectancy in USA dropped again,

Read Article

Genetic Testing for Autoinflammatory Disease

Sep 01, 2022

Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.

Read Article

Disease Activity Scoring in Adult-onset Still's disease

Aug 30, 2022

Still's disease in adults (AOSD) or children (sJIA) can have dramatic symptom severity, making it easy to gauge disease activity and response to therapy, especially at the outset. However, a validated measure of disease activity has not been agreed (for clinical trial and treatment assessments

Read Article

STING/IFN Activation Promotes ANCA-Associated Vasculitis Progression

Aug 29, 2022

Research presented in the Journal of Experimental Medicine shows that ANCA-associated vasculitis (AAV) may be propagated by pathogenic mechanisms triggering cGAS/STING/IRF3-dependent IFN-I release.

Read Article

Autoimmune Disease Augments Cardiovascular Risk

Aug 29, 2022

A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.

A population-based study examined 22,009,375 persons from the Clinical Practice Research Datalink (CPRD), GOLD and Aurum datasets.  This included

Read Article

Influenza Vaccination Recommendations

Aug 26, 2022

The CDC has published an update to the recommendations from the Advisory Committee on Immunization Practices (ACIP) on the use of seasonal influenza vaccines in the United States for the 2022-23 season.

Read Article
IL-6 IL6 cells cytokine

Olokizumab, another IL-6 Inhibitor for RA

Aug 25, 2022

This week's NEJM has published the efficacy results of a large phase 3 trial of olokizumab, a humanized monoclonal antibody that directly targets IL-6 in patients with rheumatoid arthritis.

This is in contrast to two other marketed IL-6 inhibitors (sarilumab, tocilizumab) that bind to the IL-6

Read Article

Bullous Systemic Lupus Erythematosus

Aug 24, 2022

Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).

As goes SLE, bullous disease typically affects women, especially those of African descent.

Read Article
RheumNow Podcast square

Managing JDM with Calcinosis

Aug 19, 2022

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.

  1. CDC report of fungal infx in US 2019 - coccidioidomycosis (20,061), histoplasmosis (1,124) & blastomycosis (240

Read Article
Malar,rash,SLE, Lupus

Low Dose IL-2 Therapy in SLE

Aug 17, 2022

A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE). This is not surprising as IL-2 is needed to bolster insufficient regulatory T cell (Treg) activity, thought to be pivotal to the

Read Article

Less Organ Damage with Remission in SLE

Aug 10, 2022

A cohort study of SLE patients shows that remission and low disease activity (LDA) are associated with less damage accrual over time.

Patients from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort were serially assessed with different measures of

Read Article

Utility of Repeat ENA Antibody Testing

Aug 10, 2022

Repeat serologic testing is not uncommon, but is it warranted? A retrospective study shows that repeated testing for autoantibodies to extractable nuclear antigens (ENA) rarely changes the result or adds a new diagnosis. 

This study from a single, multicentre tertiary health network

Read Article

CDC Reviews Monkeypox

Aug 08, 2022

MMWR recently reviewed the epidemiology and characteristics of U.S. monkeypox cases seen between May and July 2022. They found that 99% of cases occurred in men, 94% of whom reported recent male-to-male sexual or close intimate contact.  Current outbreak-associated cases are less likely to

Read Article

More Bad Safety News for Xeljanz

MedPage Today
Aug 08, 2022

Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.

Read Article
ACR guidance

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Aug 04, 2022

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

This guideline builds on past

Read Article
RA erosions bone ACR

The Approach to Difficult to Treat Rheumatoid Arthritis

Aug 03, 2022

Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.

D2T-RA is defined by failure of at least two different mechanism of action

Read Article
DLE discoid lupus

Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus

Aug 01, 2022

Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.

Read Article